Latest News From "The Pink Sheet" DAILY - Pfizer's Prevnar 13 Vaccine Clears FDA

ACIP's Support Of FDA-Approved Prevnar 13 Creates Opportunity For Larger Market

FDA approves Pfizer's Prevnar 13 vaccine and ACIP's recommendations set the stage for a broadened indication and a blockbuster product.   read more

 

Lack of Cladribine Answers And Dividend Cut Cloud Merck KGaA's Outlook

Merck KGaA had a difficult 2009, with revenues up 2 percent and net income flat. Product woes look set to continue in 2010.   read more

 

Anthera Takes A Haircut And Delays Its Planned Initial Stock Offering

The biotech is not de-risked enough to get the pricing it sought, as investors can be choosier, industry analyst says.   read more

 

FDA/NIH Collaboration On Regulatory Science Includes Interest In Cancer, Pain Drugs and Vaccines

Grant program is small and open-ended at the outset, but officials offer a long list of needs. A public meeting to gather input on research priorities is set for April.   read more

 

FTC's Reverse Settlement Campaign May Depend On Congress After Another Court Loss

Suit against Solvay and three generic firms is tossed out of Georgia federal court, but direct purchasers may proceed with claims that defendants filed sham litigation.   read more

 

FDA's Drug Advertising Oversight Gets A Promotion From A Division To An Office

The Division of Drug, Advertising, Marketing and Communications will consist of an office with two divisions, one to review materials for healthcare professionals and other to review direct-to-consumer promotions.   read more

 

Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up

Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.   read more

 

Perrigo Pursues OTC Reimbursement Opportunity In Emerging "ORx" Space

Perrigo says the program, which garnered about $25 million in sales its first year and is expected to generate around $40 million in 2010, allows the company to better tap OTC switches' sales potential, particularly in crossover categories where comparable therapies are available both Rx and OTC.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here